[Image from NeuroMetrix]
NeuroMetrix (NSDQ:NURO) announced today that it received FDA breakthrough device designation for its Quell technology.
Woburn, Massachusetts-based NeuroMetrix’s Quell garnered the breakthrough nod for reducing moderate-to-severe symptoms of chemotherapy-induced peripheral neuropathy (CIPN) that have persisted for at least six months following the end of chemotherapy.